ME01926B - 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat - Google Patents
6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleatInfo
- Publication number
- ME01926B ME01926B MEP-2014-154A MEP15414A ME01926B ME 01926 B ME01926 B ME 01926B ME P15414 A MEP15414 A ME P15414A ME 01926 B ME01926 B ME 01926B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- dihydro
- oxy
- pentyl
- purin
- Prior art date
Links
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 7
- LFMPVTVPXHNXOT-HNNXBMFYSA-N 6-amino-2-[(2s)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7h-purin-8-one Chemical compound C12=NC(O[C@@H](C)CCC)=NC(N)=C2NC(=O)N1CCCCCN1CCCCC1 LFMPVTVPXHNXOT-HNNXBMFYSA-N 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30301010P | 2010-02-10 | 2010-02-10 | |
| EP11709025.8A EP2534149B1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate |
| PCT/EP2011/051830 WO2011098452A1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01926B true ME01926B (me) | 2015-05-20 |
Family
ID=43836817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-154A ME01926B (me) | 2010-02-10 | 2011-02-08 | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8703754B2 (enExample) |
| EP (1) | EP2534149B1 (enExample) |
| JP (1) | JP5922587B2 (enExample) |
| KR (1) | KR101773541B1 (enExample) |
| CN (1) | CN102753553B (enExample) |
| AU (1) | AU2011214468B2 (enExample) |
| BR (1) | BR112012018904A2 (enExample) |
| CA (1) | CA2786973C (enExample) |
| DK (1) | DK2534149T3 (enExample) |
| EA (1) | EA021048B1 (enExample) |
| ES (1) | ES2525826T3 (enExample) |
| HR (1) | HRP20141258T1 (enExample) |
| IL (1) | IL220845A (enExample) |
| ME (1) | ME01926B (enExample) |
| MX (1) | MX2012009316A (enExample) |
| PL (1) | PL2534149T3 (enExample) |
| PT (1) | PT2534149E (enExample) |
| RS (1) | RS53745B1 (enExample) |
| SG (1) | SG182471A1 (enExample) |
| SI (1) | SI2534149T1 (enExample) |
| SM (1) | SMT201400196B (enExample) |
| WO (1) | WO2011098452A1 (enExample) |
| ZA (1) | ZA201205995B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| CN102666541B (zh) | 2009-10-22 | 2015-11-25 | 吉里德科学公司 | 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物 |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| PL2734186T3 (pl) | 2011-07-22 | 2019-01-31 | Glaxosmithkline Llc | Kompozycja |
| KR20240148947A (ko) | 2012-07-13 | 2024-10-11 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| SG11201500243WA (en) * | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| JP6196674B2 (ja) | 2012-08-24 | 2017-09-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | ピラゾロピリミジン化合物 |
| KR20150085081A (ko) | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| SMT201700378T1 (it) | 2012-11-20 | 2017-09-07 | Glaxosmithkline Llc | Nuovi composti |
| US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| AU2015308618B2 (en) * | 2014-08-29 | 2021-05-20 | Corium Pharma Solutions, Inc. | Microstructure array for delivery of active agents |
| JP2017533925A (ja) * | 2014-11-13 | 2017-11-16 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体 |
| WO2020110584A1 (ja) * | 2018-11-28 | 2020-06-04 | 株式会社島津製作所 | アゾ化合物の分析方法 |
| WO2025143921A1 (ko) | 2023-12-29 | 2025-07-03 | (주)셀트리온 | 안정한 약제학적 제제 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| AU679511B2 (en) | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| CA2310896A1 (en) | 1999-07-02 | 2001-01-02 | Japan Tobacco Inc. | Hcv polymerase suitable for crystal structure analysis and method for using the enzyme |
| CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| DZ3487A1 (fr) | 2001-01-22 | 2002-07-25 | Merck Sharp & Dohme | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant |
| NZ528270A (en) | 2001-03-19 | 2005-10-28 | Ono Pharmaceutical Co | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| CA2481502A1 (en) | 2002-04-04 | 2003-10-16 | Achillion Pharmaceuticals, Inc. | Hcv antiviral and cytotoxicity drug screening assay |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| PL376454A1 (en) | 2002-10-24 | 2005-12-27 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| AU2003296992A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Pyrrolidine and azetidine compounds as ccr5 antagonists |
| AU2003300902A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Piperidine derivatives as CCR5 antagonists |
| DE60324014D1 (de) | 2002-12-13 | 2008-11-20 | Smithkline Beecham Corp | Heterocyclische verbindungen alsccr5-antagonisten |
| JP2006512339A (ja) | 2002-12-13 | 2006-04-13 | スミスクライン ビーチャム コーポレーション | Ｃｃｒ５アンタゴニストとしてのインダン化合物 |
| ATE384724T1 (de) | 2002-12-13 | 2008-02-15 | Smithkline Beecham Corp | Cyclopropylverbindungen als ccr5 antagonisten |
| EP1569647B1 (en) | 2002-12-13 | 2008-08-20 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
| TWI368507B (en) | 2004-02-20 | 2012-07-21 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
| JP2007534735A (ja) | 2004-04-28 | 2007-11-29 | アロウ セラピューティクス リミテッド | 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体 |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AP2313A (en) | 2004-08-18 | 2011-10-31 | Pfizer | Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same. |
| US20060045885A1 (en) | 2004-08-27 | 2006-03-02 | Kedl Ross M | Method of eliciting an immune response against HIV |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| KR20080019213A (ko) | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| WO2007034881A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
| US20100120799A1 (en) | 2007-02-19 | 2010-05-13 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
| JP5480637B2 (ja) * | 2007-03-19 | 2014-04-23 | アストラゼネカ・アクチエボラーグ | Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物 |
| UY31531A1 (es) * | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
| US8777708B2 (en) | 2008-06-27 | 2014-07-15 | Microsoft Corporation | Targeting control in a simulated environment |
| UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
-
2011
- 2011-02-08 EA EA201290631A patent/EA021048B1/ru not_active IP Right Cessation
- 2011-02-08 PL PL11709025T patent/PL2534149T3/pl unknown
- 2011-02-08 AU AU2011214468A patent/AU2011214468B2/en not_active Ceased
- 2011-02-08 HR HRP20141258AT patent/HRP20141258T1/hr unknown
- 2011-02-08 DK DK11709025.8T patent/DK2534149T3/da active
- 2011-02-08 ME MEP-2014-154A patent/ME01926B/me unknown
- 2011-02-08 ES ES11709025.8T patent/ES2525826T3/es active Active
- 2011-02-08 BR BR112012018904-2A patent/BR112012018904A2/pt not_active IP Right Cessation
- 2011-02-08 WO PCT/EP2011/051830 patent/WO2011098452A1/en not_active Ceased
- 2011-02-08 PT PT117090258T patent/PT2534149E/pt unknown
- 2011-02-08 EP EP11709025.8A patent/EP2534149B1/en active Active
- 2011-02-08 US US13/578,020 patent/US8703754B2/en not_active Expired - Fee Related
- 2011-02-08 RS RS20150005A patent/RS53745B1/sr unknown
- 2011-02-08 CA CA2786973A patent/CA2786973C/en not_active Expired - Fee Related
- 2011-02-08 CN CN201180009082.0A patent/CN102753553B/zh not_active Expired - Fee Related
- 2011-02-08 SG SG2012051140A patent/SG182471A1/en unknown
- 2011-02-08 KR KR1020127023687A patent/KR101773541B1/ko not_active Expired - Fee Related
- 2011-02-08 JP JP2012552369A patent/JP5922587B2/ja active Active
- 2011-02-08 SI SI201130364T patent/SI2534149T1/sl unknown
- 2011-02-08 MX MX2012009316A patent/MX2012009316A/es active IP Right Grant
-
2012
- 2012-07-10 IL IL220845A patent/IL220845A/en not_active IP Right Cessation
- 2012-08-08 ZA ZA2012/05995A patent/ZA201205995B/en unknown
-
2014
- 2014-12-30 SM SM201400196T patent/SMT201400196B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2786973C (en) | 2018-04-10 |
| WO2011098452A1 (en) | 2011-08-18 |
| AU2011214468B2 (en) | 2015-05-28 |
| US20120308609A1 (en) | 2012-12-06 |
| EP2534149A1 (en) | 2012-12-19 |
| IL220845A (en) | 2016-08-31 |
| KR20120135408A (ko) | 2012-12-13 |
| DK2534149T3 (da) | 2015-01-05 |
| SG182471A1 (en) | 2012-08-30 |
| CN102753553A (zh) | 2012-10-24 |
| ES2525826T3 (es) | 2014-12-30 |
| EA201290631A1 (ru) | 2013-03-29 |
| CN102753553B (zh) | 2016-03-30 |
| PL2534149T3 (pl) | 2015-03-31 |
| HRP20141258T1 (hr) | 2015-02-27 |
| SMT201400196B (it) | 2015-01-15 |
| SI2534149T1 (sl) | 2015-02-27 |
| AU2011214468A1 (en) | 2012-08-09 |
| PT2534149E (pt) | 2014-12-23 |
| KR101773541B1 (ko) | 2017-08-31 |
| JP5922587B2 (ja) | 2016-05-24 |
| RS53745B1 (sr) | 2015-06-30 |
| BR112012018904A2 (pt) | 2020-09-01 |
| US8703754B2 (en) | 2014-04-22 |
| MX2012009316A (es) | 2012-09-12 |
| EP2534149B1 (en) | 2014-10-15 |
| JP2013519645A (ja) | 2013-05-30 |
| CA2786973A1 (en) | 2011-08-18 |
| ZA201205995B (en) | 2014-01-29 |
| EA021048B1 (ru) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01926B (me) | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat | |
| ME02274B (me) | DERIVATI PURINA ZA UPOTREBU U LEČENJU ALERGIJSKIH, INFLAMATORNIH l INFEKTIVNIH BOLESTI | |
| JP2013519645A5 (enExample) | ||
| BR112014001798A2 (pt) | compostos de tetraciclina 9-aminometila substituídos | |
| MX374497B (es) | Inhibidor del antígeno de superficie del virus de la hepatitis b. | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| JP2013542247A5 (enExample) | ||
| ME02547B (me) | Inhibitori hepatitis c virusa | |
| HRP20171512T1 (hr) | Derivati betulina | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| WO2015048662A3 (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| JP2010270124A5 (enExample) | ||
| WO2012125926A3 (en) | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | |
| BR112013026355A2 (pt) | compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico | |
| BRPI0720667A8 (pt) | Métodos de administração de vacina | |
| EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| ITMI20020808A1 (it) | Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| RU2013157398A (ru) | Композиция | |
| CO6331429A2 (es) | Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas | |
| EA200600886A1 (ru) | Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции | |
| RU2017102043A (ru) | Новое соединение (ks513), выделенное из pseudolysimachion rotundum var. subintegrum, композиция, содержащая указанное соединение в качестве активного ингредиента, для предотващения или лечения аллергического заболевания, воспалительного заболевания, астмы или хронической обструктивной болезни легких и их применение | |
| ATE546133T1 (de) | Orale dosierform mit trisubstituierten glycerin- verbindungen | |
| Datta | Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase Ⅰ trial |